Pfizer drug extends life for people with rare form of lung cancer

Lorlatinib was tested in a clinical trial of hundreds of people with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). Lorlatinib was tested in a clinical trial of hundreds of people with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). Health Health News, Wellbeing Tips, Diseases, Treatment and Nutrition | The Hindu